Skip to main content

Table 2 Characteristics of the included studies in the review

From: Effect of stem cell treatment on functional recovery of spinocerebellar ataxia: systematic review and meta-analysis

Authors (year) Participants Study Design Country Inclusion Criteria Exclusion Criteria Outcome assessed Follow-up PEDro Score
Dongmei et al. (2011) [19] n = 24 (14: SCA and 10: MSA-C)
Age: 46 years old
Non-randomized clinical trial China SCA Cardiopulmonary, renal and hepatic dysfunction, or systemic infection. ICARS and ADL 6 and 15 months 5 Points
Jin et al. (2013) [20] n = 16
Age: 39.9 ± 10.2 years old
Open label uncontrolled clinic trial China SCA1, SCA2 or SCA3, age 16–65 years old. Cardiopulmonary, renal and hepatic dysfunction, or systemic infection; tumor markers; blood pressure > 180/110 mmHg; pregnancy or breastfeeding. BBS and ICARS 3, 6 and 12 months 6 Points
Tsai et al. (2017) [21] n = 7
Age: 48.85 ± 14.75 years old
Pilot open label Phase I / IIa clinical trial Taiwan SCA 3 or MSA-C varying 10–20 on SARA Another trial with cell therapy less than 30 days, positive pregnancy test. SARA, SOT, MRI and F-FDG PET 12 months 5 Points
  1. Legends: SCA Spinocerebellar Ataxia, MSA-C Multiple System Atrophy-Cerebelar Type, SARA Scale for the Assessment and Rating of Ataxia, ICARS International Cooperative Ataxia Rating Scale, ADL Activity of Daily Living Scale, BBS Berg Balance Scale, SOT Posturography, MRI Magnetic Resonance Imaging, F-FDG PET Fluoro-D-glucose integrated with computed tomography. The diagnosis of spinocerebellar ataxia in all studies followed Harding’s diagnostic pattern with molecular confirmation